Multinational drug-maker, GlaxoSmithkline Pharmaceuticals has decided to enter into India-specific alliance, which will be for a product that is a new area for the company. With this decision to bring in niche products from other drug-majors through in-licensing deals, the company aims to expand the operations locally.
The entity’s existing alliances in the local market include ones with Daiichi-Sankyo on hypertensive Olmesartan Medoxomil, and with Astellas on anti-fungal drug Micafungin.